OsideNews:

Oceanside CA— Advanced Oxygen Therapy Inc., based in Oceanside, announced several additions to its leadership team in February.
The company, which develops noninvasive wound-healing solutions, brought aboard a new chief medical officer, strategy officer, president of U.S. operations and vice president of reimbursements, the company stated in a news release. Advanced Oxygen Therapy also launched an industry Scientific and Clinical Advisory Board.
“I am proud to have such industry powerhouses join our team,” company President and CEO Dr. Mike Griffiths said in the release. “This a testament and validation of the path we are on to significantly improve patient outcomes, lower costs and help address the health inequities associated with nonhealing wounds.”
Dr. Matthew G. Garoufalis — co-chair of the Alliance of Wound Care Stakeholders and past president of both the American Podiatric Medical Association and the International Federation of Podiatrists — joins Advanced Oxygen Therapy as chief medical officer.
The company’s new chief strategy officer, Douglas W.F. LeFort, comes to Advanced Oxygen Therapy after serving as CEO of Medtrade Products Ltd. and previously working to launch the $5.3 billion initial public offering of ConvaTec Group.
Advanced Oxygen Therapy President, USA, Chad Yount brings more than 25 years of experience in senior management, sales and marketing in the wound-care speciality to his new position, the company stated. Stacy Reel, new vice president of reimbursement and market access, also brings more than 20 years of experience to the company. Yount and Reel were also formerly affiliated with leading wound-care industry companies such as ConvaTec.
In addition to the leadership team, Advanced Oxygen Therapy has also launched a Scientific and Clinical Advisory Board of notable experts in a variety of disciplines related to wound care such as diabetic foot ulcers, venous leg ulcers and limb salvage related to podiatric, orthopedic, vascular and plastic surgeries.
“It is exciting to help guide, in conjunction with my esteemed colleagues, the clinical research and product development direction for such a dynamic company,” advisory board Chairman Dr. Andrew Boulton said in the news release. “AOTI is clearly committed to establishing the highest quality clinical evidence for its products.”
Boulton is president of the International Diabetes Federation and professor of medicine at the University of Manchester.
More information is available online: aotinc.net/about-us/.